Aztreonam/clavulanic acid in the treatment of serious infections caused by Stenotrophomonas maltophilia in neutropenic patients: case reports.
Two seriously neutropenic patients (a 23-year-old man with a promyelocytic acute myeloid leukemia [AML-M3] and a 77-year old male with an immature acute myeloid leukemia [AML-M1] diagnosis) with severe infections caused by Stenotrophomonas maltophilia were treated with aztreonam/clavulanic acid (2:1) combination. In the first patient the infection was caused by a multiresistant strain and in the second, by a strain with poor response to trimethoprim-sulfamethoxazole and other antimicrobial agents. After treatment with aztreonam/clavulanic acid both patients evolved favorably.
García Sánchez
J E
JE
Departmento de Microbiologìa y Parasitologìa, Hospital Universitario, Salamanca, Spain.
Vazquez López
M L
ML
Blazquez de Castro
A M
AM
Perez Simon
J A
JA
Gutierrez
N G
NG
Martin
I T
IT
García-Rodríguez
J A
JA
D000328:Adult; D000368:Aged; D001398:Aztreonam / Q000627:therapeutic use*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D016905:Gram-Negative Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications; D008297:Male; D009503:Neutropenia / Q000209:etiology*; D014974:Xanthomonas / Q000187:drug effects*
D002969:Clavulanic Acids; D019818:Clavulanic Acid; D001398:Aztreonam